New Jersey Attorneys Who Get Results
Meet Gary Shapiro and David
Sternlieb, two experienced New Jersey attorneys who know how
to get results. At Shapiro & Sternlieb, we are 100% dedicated
to providing our clients with the highest quality legal representation.
Through our hard work, persistence and with more than 60 years
of combined legal experience, we work hard to protect your rights.
As expert lawyers, we have the resources and knowledge to handle
complex cases. We pride ourselves on our concern for you as
an individual as well as for your legal rights.
Shapiro & Sternlieb: New Jersey Personal Injury Lawyers
At Shapiro & Sternlieb, your case is our priority. Our attorneys
combine outstanding client services with a thorough knowledge of
the law and a firm understanding of the latest technology available.
Our vast network of legal, medical and professional experts are
available to present the best case for you. Located in Manalapan,
New Jersey, our lawyers maintain flexible hours to meet your needs.
We offer morning, evening or weekend hours, as well as visits
to home or hospital, if needed. Our attorneys and staff bring the
highest standards of expertise, preparation, concern, diligence,
integrity and skill to each case. We take time to return your calls
and to ensure each question is answered. You are included every
step of the way!
News & Articles
Practice Areas
|
FDA Consumer Health Information Updates
http://www.fda.gov/AboutFDA/ContactFDA/StayInformed/RSSFeeds/Consumers/rss.xml
Fri, 03 Feb 2012 13:52:00 -0500
This page contains links to all past Consumer Update Analytics web pages. |
Wed, 25 Jan 2012 12:16:00 -0500
FDA gives updated safety information on ADHD drugs and heart disease in adults, dietary supplements that could be contaminated with Salmonella, and a blood thinner that may lead to bleeding problems. Learn about these and other safety alerts at http://www.fda.gov/ForConsumers/ConsumerUpdates/ucmXXXXXX.htm |
Thu, 12 Jan 2012 14:26:00 -0500
Learn how to report a bad reaction to a beauty, personal hygiene or makeup product. Click here to find out how to connect to this 30-minute webinar. |
Fri, 06 Jan 2012 13:00:00 -0500
Don't be fooled by unscrupulous people who offer hope through unapproved stem cell therapies for diseases or conditions for which few treatments exist. |
Wed, 28 Dec 2011 11:00:00 -0500
The Food and Drug Administration is taking steps to ensure that reusable medical devices, especially endoscopes, are properly cleaned and disinfected to reduce the risk of infection. |
Food and Drug Administration--Press Releases
http://www.fda.gov/AboutFDA/ContactFDA/StayInformed/RSSFeeds/PressReleases/rss.xml
Wed, 01 Feb 2012 09:48:00 -0500
The FDA and representatives from the medical device industry have reached an agreement in principle on proposed recommendations for the third reauthorization of a medical device user fee program. The recommendations would authorize the FDA to collect $595 million in user fees over five years, plus adjustments for inflation. Details of the agreement, such as the fee structure, are expected to be finalized soon. |
Tue, 31 Jan 2012 17:29:00 -0500
The U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST). Today’s action also highlights an increase in overall patient survival when the drug is taken for 36 months rather than the standard 12 months of treatment. |
Tue, 31 Jan 2012 10:59:00 -0500
The U.S. Food and Drug Administration today approved Kalydeco (ivacaftor) for the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene. |
Tue, 31 Jan 2012 10:13:00 -0500
The U.S. Food and Drug Administration is asking a federal court to prevent a New York cheese manufacturer from operating because of a history of unsanitary conditions and producing cheese in a facility contaminated with Listeria monocytogenes bacteria. |
Mon, 30 Jan 2012 10:58:00 -0500
Today, Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body (metastatic). |
US Consumer Product Safety Commission - Recent Recalls and Product Safety News
http://www.cpsc.gov
Fri, 03 Feb 2012 18:00:00 GMT
The front wheel can break at the axle hub, causing the stroller to tip and posing a fall hazard. |
Fri, 03 Feb 2012 17:00:00 GMT
The snaps can detach from the fabric of the garment, posing a choking hazard to infants and young children. |
Fri, 03 Feb 2012 16:00:00 GMT
The furnace can overheat and cause the heat-exchanger to crack and create openings that allow flames to be exposed. When this happens, drywall and other nearby combustibles are exposed to the flames, posing a fire and smoke hazard to consumers. |
Thu, 02 Feb 2012 16:00:00 GMT
The fax machines can overheat due to an internal electrical component failure, posing fire and burn hazards. |
Thu, 02 Feb 2012 15:30:00 GMT
The welding joints on the legs can break, posing a fall hazard to consumers. |
|